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Background: Two Leishmania major ribosomal proteins L3 (LmL3) and L5 (LmL5) have been described as
protective molecules against cutaneous leishmaniasis due to infection with L. major and Leishmania braziliensis in
BALB/c mice when immunized with a Th1 adjuvant (non-methylated CpG-oligodeoxynucleotides; CpG-ODN). In the
present study we analyzed the cross-protective efficacy of an LmL3-LmL5-CpG ODN combined vaccine against
infection with Leishmania amazonensis and Leishmania chagasi (syn. Leishmania infantum) the etiologic agents of
different clinical forms of human leishmaniasis in South America.
Methods: The combined vaccine was administered subcutaneously to BALB/c mice. After immunization the cellular
and humoral responses elicited were analyzed. Mice were independently challenged with L. amazonensis and L.
chagasi. The size of the cutaneous lesions caused by the infection with the first species, the parasite loads and the
immune response in both infection models were analyzed nine weeks after challenge.
Results: Mice vaccinated with the combined vaccine showed a Th1-like response against LmL3 and LmL5. Vaccinated
mice were able to delay lesion development due to L. amazonensis infection and to control parasite loads in the site of
infection. A reduction of the parasite burden in the lymph nodes draining the site of infection and in the liver and
spleen was observed in the vaccinated mice after a subcutaneous infection with L. chagasi. In both models of infection,
protection was correlated to parasite antigen-specific production of IFN-γ and down-regulation of parasite-mediated
IL-4 and IL-10 responses.
Conclusions: The data presented here demonstrate the potential use of L. major L3 and L5 recombinant ribosomal
proteins for the development of vaccines against various Leishmania species.
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Infection with different species from the genus Leishmania
can cause a variety of clinical symptoms known globally
as leishmaniasis [1]. Although some veterinary vaccines
against leishmaniasis are now available [2-4] no vaccine
has been developed for humans. During the last few years
some advances in the development of vaccines against
leishmaniasis have been carried out [5]. Given that first
generation vaccines using crude parasite antigens were
unable to induce protection [6] two main strategies have
been explored for the development of anti-Leishmania
vaccines. The first one employ live vaccines composed of
molecularly modified attenuated parasites (leishmanization)
to induce protective anti-Leishmania immune responses
[7,8]. Alternatively, second generation vaccines are based
on the use of parasite protein fractions [9,10] or individual
parasite antigens [11]. Although some of these second
generation vaccines are currently used in human clinical
trials [12] the screening of new candidates will help to fur-
ther increase the prophylactic efficacy of a Leishmania
vaccine. It has been proposed that combination of diffe-
rent parasite antigens may help to attain a vaccine con-
taining the most appropriate protective characteristics [5].
In addition, since multiple Leishmania species are distri-
buted in the same or adjacent geographical regions [13] it
would be desirable to develop vaccines containing candi-
dates capable of inducing protection against the infection
caused by various Leishmania species. One example of this
situation is South America where the leishmaniasis disease
ranges from visceral forms (VL) caused by Leishmania
chagasi (syn. Leishmania infantum [14]) infection, to cuta-
neous forms (CL) caused by infection with different para-
site species such as Leishmania braziliensis, Leishmania.
pifanoi and Leishmania amazonensis. All these species can
coexist in different geographical regions [13]. Thus, to be
effective as a human vaccine against leishmaniasis its com-
ponents should be shared by different parasite species and,
prior to its use in humans, the protective efficacy of these
candidates should be analyzed in different models of ex-
perimental leishmaniasis.
Examples of such vaccine preparations are those based
on parasite ribosomal proteins. It has been demonstrated
that a preparation of biochemically purified Leishmania
ribosomal proteins (LRP) administered in combination with
Th1 inducing adjuvants conferred protection against the
challenge with different parasite species: L. amazonensis
and L. chagasi [15] or L. major promastigotes [16]. Also,
vaccinated and protected BALB/c mice were able to
control the disease due to a secondary parasite chal-
lenge [17]. It was recently reported that two of the large
subunit constituents of L. major ribosomes L3 or L5,
expressed as recombinant proteins (LmL3 and LmL5)
and administered independently or in combination (al-
ways in the presence of a Th1 adjuvant such as non-methylated CpG-oligodeoxynucleotides; CpG-ODN) were
able to control the outcome of infection in an experi-
mental model of American CL, namely BALB/c mice in-
fected with L. braziliensis [18]. Globally, it was found
that protection was associated with both, the induction
of LRP-, LmL3- or LmL5-specific IFN-γ mediated re-
sponses and the control of the antigen dependent pro-
duction of the susceptibility associated cytokines IL-10
and IL-4 [19].
The first objective of the study was to analyze the im-
munogenic properties of a vaccine combining the LmL3
and LmL5 recombinant proteins and CpG-ODN as adju-
vant in BALB/c mice. The second objective was to study
the combined vaccine prophylactic properties, challen-
ging immunized mice with two different Leishmania
species: L. amazonensis and L. chagasi. The potential
mechanism of the combined vaccine-induced observed
protection was also investigated and is consistent with
the maintenance of the Th1-like response against the
LmL3 and LmL5 antigens induced by vaccination after
infection.
Methods
Antigens and adjuvant
Soluble Leishmania antigenic (SLA) extract was prepared
from stationary-phase promastigotes of L. major, L. chagasi
and L. amazonensis as previously described [20]. L. major
ribosomal proteins (LRP) or mouse ribosomal proteins
(MRP) were prepared from logarithmic-phase promasti-
gotes of L. major and RAW 264.7 murine macrophage
cells, respectively, as previously described in [10].
LmL3 and LmL5 recombinant proteins were over-
expressed in Escherichia coli (M15 strain), purified under
denaturing conditions onto Ni-nitrilotriacetic-acid-agarose
columns (Qiagen, Hilden, Germany) and refolded on the
affinity column, as described in [21]. Polymyxin-agarose
columns (Sigma, St. Louis. MO, USA) were employed to
remove residual endotoxin content (<10 ng of LPS per
1 mg of recombinant protein, measured by the Quantita-
tive Chromogenic Limulus Amebocyte Assay QCL-1000
(BioWhittaker, MD, USA)).
Phosphorothioate-modified CpG-ODN (5′-TCAACGT
TGA-3′ and 5′- GCTAGACGTTAGCGT-3′) were syn-
thesized by Isogen Life Science B.V. (De Meern, The
Netherlands) and employed for their capacity to induce
Th1 responses in mice when immunized with different
leishmanial antigenic preparations [16,22].
Immunization, challenge infection, cutaneous lesion
development and parasite quantitation
The Bioethical Committee of the Consejo Superior de
Investigaciones Científicas (CEEA-11/046) and the Univer-
sidad Autónoma de Madrid (CEI 21–443) in Spain and the
Animal Use Committee of the Federal University of Minas
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mental. Mice (n = 4 or 5) were subcutaneously (s.c.) immu-
nized in their left hind footpads with a mixture of the
LmL3 and LmL5 recombinant proteins (6 μg each) plus 25
μg of each CpG-ODN (combined vaccine). As control
groups, mice (n = 4 or 5) were inoculated with 25 μg of
each CpG-ODN or with saline (PBS; vaccine diluent). Each
group was boosted two and four weeks later with the same
dose. For challenge, immunized mice were s.c. infected, into
the right hind footpad, with 1 × 107 stationary-phase pro-
mastigotes of L. chagasi (n = 4, per group) or with 1 × 106
stationary-phase promastigotes of L. amazonensis (n = 4
per group). In mice infected with L. amazonensis, footpad
swelling was measured with a metric caliper (the thickness
of the left footpad minus thickness of the right footpad is
shown). At week nine post-challenge all animals were sacri-
ficed. For parasite load determination, the footpads of mice
infected with L. amazonensis were taken and weighed be-
fore their individual processing. In addition the whole
spleen, liver and the single popliteal lymph node draining
the site of infection (DLN, right leg) of mice s.c. infected
with L. chagasi were collected and independently processed
as follows. Samples were mechanically homogenized in
complete Schneider’s medium (Schneider’s medium
(Sigma) supplemented with 20% heat-inactivated fetal bo-
vine serum (FBS, Sigma), 20 mM L-glutamine, 200 U/ml
penicillin, 100 μg/ml streptomycin and 50 μg/ml gentami-
cin) and filtered using a cell strainer (70-μm pore size).
Each homogenized sample tissue was serially diluted in a
96-well flat-bottomed microtiter plate containing the same
medium (in triplicates). The number of viable parasites (by
mg of tissue for the footpads and by organ in the spleen,
liver and DLN) was determined from the highest dilution
at which promastigotes could be grown with up to 10 days
of incubation at 25°C as previously described [23].
Mice and parasites
Female BALB/c mice (6–8 weeks old) were purchased
from Harlan (BCN, Spain) or from the Institute of Bio-
logical Sciences, ICB, Federal University of Minas Gerais
(Belo Horizonte, Brazil). First, the immunization pro-
cedure was carried out using a total number of 15 mice
(5 mice immunized with saline, 5 mice immunized with
the adjuvant and 5 mice immunized with the combined
vaccine). Mice were euthanized one month after the last
immunization for the analysis of the immune response
elicited by vaccination. Next, mice were immunized sub-
cutaneously with the combined vaccine (n = 12), with
the vaccine diluent (n = 12) or with the vaccine adjuvant
(n = 12). One month after vaccination, 4 mice per group
were euthanized to test the reproducibility of the vac-
cine induced response. The remaining animals were in-
fected s.c. with L. amazonensis (n = 4 mice per group) or
L. chagasi (n = 4 per group) to analyze the effect ofvaccination in leishmaniasis progression. This last assay
was reproduced using the same number of mice.
Regarding parasites, L. major clone V1 (MHOM/IL/80/
Friedlin), L. chagasi (MOM/BR/1970/BH46) and L.
amazonensis (IFLA/BR/1967/PH-8) parasites were grown
at 25°C in complete Schneider’s medium.
Cytokine production
Spleen cells obtained from each mouse were seeded and
independently cultured in RPMI complete medium at
5 × 106 cells per ml (RPMI medium (Sigma) supplemented
with 10% heat-inactivated FBS, 20 mM L-glutamine, 200
U/ml penicillin, 100 μg/ml streptomycin and 50 μg/ml
gentamicin) during 48 h at 37°C in 5% CO2 alone or with
some of the next stimuli: recombinant LmL3 (12 μg/ml),
recombinant LmL5 (12 μg/ml), SLA (from the indicated
species, 12 μg/ml), LmLRP (12 μg/ml) and MRP (12 μg/ml).
The release of IFN-γ, IL-10 and IL-4 was measured in cul-
ture supernatants by sandwich ELISA using monoclonal
antibodies specific for mouse cytokines (capture and detec-
tion) provided in commercial kits (Pharmingen, San Diego,
CA, USA), following the manufacturer’s instructions.
Analysis of the humoral responses
Animals (n = 4 per group) were bled four weeks after the
last immunization and nine weeks after challenge and
the anti-LmL3-, anti-LmL5- or anti-SLA specific IgG1
and IgG2a antibodies present in the sera were measured
by ELISA, as described elsewhere [20]. Briefly, 96-well
plates (Becton Dickinson, Franklin Lakes, NJ, USA) were
sensitized with the recombinant proteins or SLA (from
the indicated species) at 10 μg/ml (each one) in PBS
(100 μl/well) for 16 h at 4°C. Plates were blocked with
PBS-10% bovine serum albumin at 37°C for 1 h and
treated with 1/200 dilutions of mouse serum samples for
2 h at 37°C. Peroxidase-conjugated anti-mouse IgG1 or
IgG2a isotype (Sigma) was diluted at 1:5,000 (for recom-
binant proteins) or 1:10,000 (for SLA) and added for 1 h
at 37°C. Reactions were developed by incubation with
H2O2 and O-phenylenediamine. Optical densities were
read at 492 nanometers in a spectrophotometer (Mo-
lecular Devices, Spectra Max Plus, Concord, Canada).
Statistical analysis
Statistical analysis with the vaccinated and infected mice
was performed by a two-tailed Student’s t-test. Differ-
ences were considered significant when P < 0.05.
Results and discussion
Immunogenicity of the LmL3 + LmL5 + CpG-ODN
combined vaccine in BALB/c mice
Since combination of different parasite protective anti-
gens have been defined as an adequate strategy for
Leishmania vaccine development [24,25] we decided to
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on the observation that both proteins were able to induce
protection against murine CL due to L. major infection
[19]. Moreover, administration of the CpG-ODN adjuvant
combined with these antigens as single or combined vac-
cines induced a robust protection in mice against infection
with a mixture of L. braziliensis stationary-phase promas-
tigotes and insect vector saliva, while no protection was
observed when animals were only treated with CpG-ODN
[19]. However, the immune response elicited against the
antigens by their co-administration was not analyzed in
that work.
From an immunological point of view, we show that
spleen cells from mice immunized with the combined0
500
1000
1500
2000
2500
3000
LmL3 LmL5 LmSLA LmLRP MRP Medium
Saline
CpG
LmL3+LmL5+CpG
IF
N
-γ
 (p
g/m
l) 
*
*
*
0
100
200
300
400
500
LmL3 LmL5 LmSLA LmLRP MRP Medium
Saline
CpG
LmL3+LmL5+CpG
IL
-4
 (p
g/m
l) 
O
.
D.
 
(49
2 n
m
) 
A B
C D
Figure 1 Cellular and humoral responses in BALB/c mice immunized
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mice and both control groups. Data shown are representative of at least twovaccine were able to secrete LmL3- and LmL5-specific
IFN-γ, since significantly higher levels of this cytokine
were found in the culture supernatants after stimulation
with these antigens, when compared with the culture su-
pernatants established from control mice, namely saline
(P = 0.0006 for LmL3 and P = 0.0002 for LmL5) and CpG-
ODN groups (P = 0.0002 for both antigens) (Figure 1A).
The presence of the CpG-ODN, an agonist of the TLR9
[26] that confers a Th1-related long-term immunity and
protection when combined with different leishmanial anti-
gens [22] was essential for the stimulation of the antigen
specific IFN-γ response, since low levels of this cytokine
were produced when the LmL3 + LmL5 proteins were co-
administered in the absence of the adjuvant (not shown).0
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duced when each one of the antigens was administered in
the presence of the same adjuvant [19]. The LmL3 and
LmL5 combined vaccine also induced similar patterns of
IL-10 and IL-4 secretion than single based vaccines [19].
Spleen cells from vaccinated mice showed a slightly higher
production of IL-10 than control mice groups when stim-
ulated with LmL5, although the differences were not sig-
nificant (Figure 1B). Very low similar levels of IL-4 were
detected in vaccinated and control groups after stimula-
tion with both recombinant proteins (Figure 1C). In
addition, vaccinated mice showed a specific anti-LmL5
humoral response that was predominantly of the IgG2a
isotype (P = 0.01 compared with saline and CpG-ODN
groups) although IgG1 antibodies specific for this anti-
gen were also observed in the sera from immunized
mice (P = 0.03 compared with saline and CpG-ODN
groups) (Figure 1D). It can be concluded that the vac-
cine combining LmL3, LmL5 and CpG-ODN induced a
predominant Th1-like response for both antigens of differ-
ent magnitude, stronger for LmL5 than for LmL3, because
of the robust production of LmL5-specific IFN-γ and by
the presence of anti-LmL5 IgG2a antibodies, markers of
Th1-type responses [27]. The immune response elicited
against the recombinant proteins was correlated with a
production of IFN-γ when L. major ribosomes (LmLRP)
were employed for in vitro stimulation (Figure 1A;
LmLRP). The lack of LmSLA-specific production of cyto-
kines (Figure 1A-C; LmSLA) may be related to the lower
contents of ribosomal proteins in a total parasite extract
when compared to the LmLRP preparation.
Leishmania LmL3 and LmL5 proteins were selected for
a cross-protection analysis due to their high degree of
conservation among different Leishmania species [19]. On
the other hand, and regarding host counterparts, L. major
LmL3 and LmL5 showed lower identity and similarity
scores with respect to their mouse homologs: Mus
musculus L3 (NCBI: NP_038790.2), identity: 59.4%, simi-
larity: 74.0%; Mus musculus L5 (NCBI: NP_000960.2),
identity: 53.4%, similarity: 68.5%. Remarkably, no humoral
or cellular responses against host ribosomal proteins were
observed in vaccinated mice (Figure 1A-D; MRP). This
lack of immune cross-reactivity between parasite and host
intracellular proteins belonging to conserved families was
also observed for other intracellular antigens, such as his-
tones and heat shock proteins in infected individuals [28].
This observation has been related to the location of B and
T cell epitopes in the most divergent regions of these para-
site proteins [28-30].
Effects of vaccination in the development of CL due to
L. amazonensis and VL due to L. chagasi in BALB/c mice
Since the development of vaccines against leishmaniasis
requires the definition of potential candidates capable ofinducing protective responses against different Leish-
mania species [12], we evaluated the protective efficacy
of the combined vaccine (LmL3 + LmL5 + CpG-ODN) in
two different forms of murine leishmaniasis. The first
one was a model of infection with a high dose of L.
amazonensis stationary promastigotes in the footpad of
BALB/c mice. This highly pathogenic species is able to
cause different forms of American Tegumentary leish-
maniasis (ATL) and VL in humans and a severe CL in
mice [31,32]. Mice immunized with the combined vac-
cine showed a reduction in the lesion size when com-
pared with control mice groups immunized with saline
or with the adjuvant alone (Figure 2A). Differences were
significant until nine weeks after infection when com-
pared with saline and until seven weeks when compared
with CpG-ODN group (Figure 2A). At the end of the
assay (nine weeks after challenge), the parasite burdens
found in the infected footpads were lower in vaccinated
mice than in both controls groups (Figure 2B).
The decrease in parasite loads in the infected footpads
was statistically significant when compared with both
groups (P = 1.6 × 10-5 and P = 4.5 × 10-5 for saline and
CpG-ODN groups, respectively). It was concluded that al-
though the administration of the adjuvant alone could
have a slight influence on the outcome of infection, the
administration of the combined vaccine induced a delay of
the progressive disease due to the L. amazonensis chal-
lenge. The BALB/c-L. amazonensis model of infection has
been employed for a limited number of antigenic prepara-
tions including some antigens described as protective in
other forms of the disease like the LACK protein or
the amastigote A2 antigen (reviewed in [11]) and the
Leishmania P4 nuclease, a protein immunogenic in hu-
mans infected with L. major [33] and related to protection
against experimental murine L. pifanoi infection [34].
Among them, the most protective formulation was based
on defined antigens administered in combination with IL-
12: P4 nuclease [35] or the A2 protein [20], since no foot-
pad swelling was observed after L. amazonensis challenge.
Although it is difficult to establish a direct comparison
between different vaccine candidates (due to the use of
different parasite strains, number of parasite in the in-
oculum, adjuvants employed, etc.), the combined vaccine
assayed here seems to be inducing weaker protection than
vaccines that employ IL-12 as adjuvant, a cytokine that
plays a central role in promoting Th1 responses and cell-
mediated immunity [36]. The effects of the combined vac-
cine are more comparable with other vaccines based on
parasite total proteins [37-39], antigenic extracts [38-40]
including LRP + saponin [15] and some DNA vaccines
based on the A2 [41] or LACK [39] proteins, that induced
a delay in the footpad swelling. Of interest, the 4.5-log re-
duction observed in the footpad parasite loads of
mice vaccinated with the LmL3 + LmL5 + CpG-ODN
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Figure 2 Effect of the vaccination in murine leishmaniasis due to L. amazonensis or L. chagasi infection. Mice (four per group) immunized
with vaccine diluent (Saline) with CpG-ODN adjuvant (CpG) or with the recombinant vaccine (LmL3 + LmL5 + CpG) were independently challenged
subcutaneously in the left footpad with 1 × 106 stationary-phase promastigotes of L. amazonensis (A-B) or 1 × 107 stationary-phase promastigotes of
L. chagasi (C). (A) Lesion development was monitored weekly during nine weeks in mice infected with L. amazonensis. The mean ± standard deviation
(SD) of the footpad swelling is given as the difference of thickness between the infected and the uninfected contralateral footpad. P values
(saline immunized versus vaccinated or CpG-ODN immunized versus vaccinated) are included in the table below the graph. (B) Parasite burden
was determined in the infected footpads (parasites per mg) nine weeks after infection with L. amazonensis. Mean + SD is shown. * P < 0.05
indicates significant decrease in the footpad parasite burdens between vaccinated and both control groups. (C) Parasite burdens (parasites per
organ) in the spleen, in the liver and in the popliteal lymph node draining the infected footpad (DLN) after L. chagasi infection. Mean + SD of
four mice in each group is shown. P values (saline immunized versus vaccinated or CpG-ODN immunized versus vaccinated) are included in the
table at the right of the graph. Data shown are representative of two independent experiments with similar results.
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was comparable in magnitude with parasite burden dif-
ferences observed in mice vaccinated with the most
protective formulations and their controls [20,35,41].
Moreover, it should be taken into account that some
antigen-based vaccines, such as LACK combined with
IL-12 [20] or a DNA vaccine based on a Nucleoside
Hidrolase [41] an antigen that induces partial protec-
tion against other Leishmania species [34], were unable
to control murine CL due to L. amazonensis infection.
In addition, some parasite serine-proteases were able to
exacerbate the L. amazonensis related disease when im-
munized as a prophylactic preparation alone or com-
bined with saponin [42].A great number of different molecules have been tested
as second generation vaccines in murine models of VL in-
fection [43]. Most of the tested antigens were studied
using the intravenous route of infection that guarantee the
induction of VL but could undervalue the potential effi-
cacy of some vaccines [44]. We decided to subcutaneously
challenge L. chagasi in the footpad of BALB/c mice be-
cause this model has been accepted as an optimal
screening tool to analyze protective antigens [45] and
has been previously employed to test the immunopro-
phylactic properties of different parasite components
[46,47], including the combination of LRP and saponin
[15]. As it is shown in Figure 2C the L. chagasi challenge
resulted in parasite active infection with the presence of
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ling) but also in the spleen and in the liver, internal
organs involved in parasite replication in murine VL
[48]. Nine weeks after infection, mice immunized with
LmL3 + LmL5 + CpG-ODN showed significantly lower
parasite burdens than both control groups in the three
analyzed organ locations (Figure 2C). The decrease of
parasite loads in the vaccinated mice was more evident
in the internal organs (2.5-log reduction in the liver and
in the spleen when compared with saline group and
2-log reduction in the liver and in the spleen when com-
pared with the CpG-ODN group). A significant decrease
in the parasite burdens of the lymph node draining the
infected footpad (2-log and 1.5-log reduction when
compared with saline and CpG-ODN groups, respec-
tively) was also observed. As it also occurred after L.
amazonensis challenge (the present study) and other cu-
taneous species (L. major and L. braziliensis [19]) vac-
cinated mice were able to control the replication of
different Leishmania species, allowing the conclusion
that LmL3 and LmL5 based vaccines will fit the require-
ments to a pan-Leishmania vaccine.
Immunological parameters associated with protection
To determine the immunological parameters of protec-
tion, the production of different cytokines in the super-
natants of spleen cell cultures, established from the
different groups of mice and stimulated with different
antigenic preparations was analyzed.
First, the post-infection response against the antigens
composing the vaccine was examined. Vaccinated and
infected mice showed an IFN-γ LmL3- and LmL5-
specific production that was absent in the infected con-
trol groups. A significant increase in the level of this
cytokine in the supernatant of vaccinated versus saline
and CpG spleen cells cultures was observed after stimu-
lation with LmL3: P = 0.0006 for both antigens in L.
amazonensis infected mice (Figure 3A) and P = 0.0008
and P = 0.0007, respectively, in L. chagasi infected mice
(Figure 3B). Similarly, stimulation with LmL5 resulted in
the secretion of higher levels of IFN-γ in vaccinated than
in saline and CpG control mice groups: P = 0.0008
for both antigens in L. amazonensis infected mice
(Figure 3A) and P = 2 × 10-5 and P = 3 × 10-5, respec-
tively, in L. chagasi infected mice (Figure 3B). We did
not detect antigen specific IL-4 or IL-10 production after
stimulation with the recombinant LmL3 or LmL5 pro-
teins in the vaccinated and infected mice. Thus, it was
concluded that after challenge the Th1-like response
elicited against the LmL3 and LmL5 ribosomal proteins
by the vaccine was maintained. Following infection, cel-
lular responses elicited against LmL5 were higher than
those detected against LmL3. The different immuno-
genic properties of the two recombinant proteins werealso observed in the humoral responses elicited against
both proteins in the infected mice. In both mouse
models, L. amazonensis vaccinated and infected mice
(Figure 4A) or L. chagasi vaccinated and infected mice
(Figure 4B) the reactivity against LmL5 was stronger
than against LmL3, as also occurred in mice vaccinated
with these proteins after L. major infection [19]. In the
L. amazonensis model higher IgG2a anti-LmL3 and anti-
LmL5 antibody reactivity were observed in vaccinated
than in saline mice groups (P = 0.0063 and P = 0.0006,
respectively) or in CpG-ODN immunized mice (P =
0.002 and P = 0.001, respectively) (Figure 4A). After L.
chagasi infection only the IgG2a anti-LmL5 antibodies
showed higher reactivity in vaccinated than in control
mice (P = 0.002 saline and P = 0.003 CpG-ODN)
(Figure 4B).
The systemic cellular response in infected BALB/c
mice against L. amazonensis parasite total proteins was
analyzed by LaSLA (prepared from this parasite specie)
stimulation of spleen cell cultures established from sa-
line and CpG-ODN control groups. SLA specifically in-
duced the secretion of IL-4 and IL-10 production in the
absence of IFN-γ production in both infected control
groups (Figure 3A). This low T- cell response also re-
ported for other experimental infections performed with
L. amazonensis [15,20,41,49] can negatively affect the ac-
tivation of the effector functions of macrophages for
destroying the intracellular amastigotes [31,50]. On the
contrary, after infection vaccinated mice mounted a
LaSLA-specific IFN-γ mediated response (vaccinated
mice versus saline [P = 0.0005] or CpG-ODN [P =
0.0006] groups) (Figure 3A), that may be activating the
macrophages for destruction of parasites at the infection
site, resulting in the observed decrease of the parasite
load shown in Figure 2B. As reported here, induction of
parasite specific IFN-γ responses by vaccination was also
related to protection induced by parasite lysates
[15,38,39] or single parasite proteins based vaccines
[35,39]. In addition, a decrease in the LaSLA-mediated
IL-4 and IL-10 responses was observed in the vaccinated
and infected mice (Figure 3A). A comparison between
saline and CpG-ODN controls and protected mice re-
vealed that spleen cells from vaccinated mice produced
significantly lower amounts of IL-4 (P = 2 × 10-5 and P =
0.0002, respectively) and IL-10 (P = 0.002 and P = 0.0001,
respectively). A decrease in IL-10 was correlated with
protection induced by the P4 Hidrolase protein + IL-12
vaccine [35] and a decrease of IL-4 and IL-10 parasite-
specific mediated responses was also observed in mice
protected by the administration of LRP + saponin [15],
although the exact role of these cytokines in the devel-
opment of lesions due to L. amazonensis is not fully
understood [31]. The humoral responses elicited against
total parasite proteins were in accordance with the
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vaccine diluent (Saline), with CpG-ODN adjuvant (CpG) or with the recombinant vaccine (LmL3 + LmL5 + CpG) were independently challenged
subcutaneously in the left footpad with 1 × 106 stationary- phase promastigotes of L. amazonensis (A) or 1 × 107 stationary-phase promastigotes
of L. chagasi (B). Nine weeks after infection, spleen cell cultured suspensions were non-stimulated (Medium; background control) or separately
stimulated with recombinant LmL3 or LmL5 (12 μg/ml each one) or with SLA from L. amazonensis (LaSLA; A) or L. chagasi (LcSLA, B) at 12 μg/ml
each one for 48 h at 37°C, 5% CO2. IFN-γ , IL-4 and IL-10 levels were measured in culture supernatants by ELISA. Mean + standard deviation (SD)
of cytokine levels determined in four individual mice per group is shown; *, P < 0.05 indicates significant cytokine production increase between
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similar results.
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http://www.parasitesandvectors.com/content/7/1/3cellular responses induced by infection, since anti-LaSLA
antibodies found in the vaccinated mice were mainly of
the IgG2a isotype, being the anti-LaSLA reactivity of the
IgG1 isotype antibodies significantly lower than those de-
tected in both control groups (P = 0.0006 versus saline
and P = 0.0007 versus CpG-ODN, respectively) (Figure 5).
Similarly, when the cellular responses elicited in BALB/c
mice infected with L. chagasi against the LcSLA (using ex-
tracts prepared from this parasite specie) were analyzed, a
LcSLA-specific production of IFN-γ was detected in thevaccinated mice that was absent in saline (P = 5 × 10-9) or
CpG-ODN (P = 4 × 10-7) groups (Figure 3B). This re-
sponse was correlated to the predominant presence of
anti-LcSLA IgG2a antibodies in the sera from vaccinated
and infected mice (Figure 5). Since IFN-γ dependent acti-
vation of infected macrophages for production of nitric
oxide is necessary for Leishmania intracellular killing [51]
this cytokine has been considered one of the main factors
implicated in the acquired immunity against infection with
viscerotropic Leishmania species [15,41,52,53]. IL-10
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ELISA for specific anti-LmL3 and anti-LmL5 antibody responses of both
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Figure 5 Humoral response against soluble parasite antigens
(SLA) antigens following infection with L. amazonensis or L.
chagasi. Nine weeks after parasite challenge vaccinated and
control mice (n = 4 per group) were bled and sera were individually
tested by ELISA for specific anti-SLA antibody responses of both
IgG1 and IgG2a isotypes at 1/200 dilution. Each bar represents the
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Data shown are representative of two independent experiments with
similar results.
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[54], since BALB/c mice lacking the gene for IL-10 [55] or
BALB/c mice treated with an anti-IL-10 receptor antibody
[56] are resistant to infection. In accordance, mice vacci-
nated with the LmL3 + LmL5 + CpG-ODN combined vac-
cines showed a specific decrease in the LcSLA-mediated
IL-10 (P = 0.0004 for saline and P = 8 × 10-7 for CpG-
ODN) (Figure 3B) and also a controlled production of IL-4
specific for the parasite antigens (P = 7 × 10-5 for saline
and P = 2 × 10-5 for CpG-ODN) (Figure 3B) correlated to
the presence of low levels of anti-LcSLA IgG1 reacting
antibodies (Figure 5). Although the implication of IL-4 me-
diated responses in murine VL progression has not been
clearly demonstrated, various reports have correlated the
induction of protection against a subcutaneous challengewith L. chagasi to the control of Leishmania-specific IL-4
mediated responses [15,41,46,47].
Conclusions
The present study indicated that the administration of a
vaccine based on the combination of the recombinant ver-
sions of the L. major ribosomal proteins L3 and L5 in the
presence of a Th1 adjuvant (CpG-ODN) conferred cross-
protection in BALB/c mice against subcutaneous infection
with two different Leishmania species: L. amazonensis and
L. chagasi. After vaccination, mice showed an LmL3, LmL5
and LRP (Leishmania ribosomal proteins) Th1-like re-
sponse as shown by the production of IFN-γ specific for
these antigens, in the absence of IL-10 or IL-4-specific re-
sponses. In spite of the conserved nature of the ribosomal
proteins, vaccinated mice did not show cellular and
humoral responses against the ribosomal protein of the ver-
tebrate host (MRP extract). The immune response against
LmL3 and LmL5 elicited by the combined vaccine was
maintained after infection in the vaccinated and protected
mice. Protection was also correlated with the induction of
parasite dependent IFN-γ responses and with the down-
regulation of parasite dependent IL-4 and IL-10 responses.
Since LmL3 and LmL5 based vaccines were able to induce
protection against different Leishmania species in BALB/c
mice (L. amazonensis and L. chagasi; this work) and other
cutaneous species such as L. major and L. braziliensis [19]
we may conclude that these antigens could play a relevant
role as components of a pan-Leishmania vaccine.
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